Choosing a Metabolic Disease Model

Four questions decide the tier. The model does not decide the question.

Four questions before the model

QuestionWhy it decides the tier
Which tissue lost control?Determines the cell type, and whether a monoculture suffices
What timescale is the phenotype?Hours needs a cell system; months needs an animal or a cohort
Is a systemic component part of the mechanism?If yes, no dish can model it
Does the outcome require architecture?Fibrosis, gradients and barrier function need 3D or tissue

A model chosen before these four are answered is usually chosen by convenience, and the resulting claim is usually narrower than the paper states.

The tiers

TierSupportsCannot supportTypical time
Immortalised lineMechanism, screening, dose–responseTissue identity, systemic effects, chronic set pointDays–weeks
Primary cellPhysiological metabolism, short-term regulationLong-term adaptation; dedifferentiation within daysDays
iPSC-derivedGenotype-defined, patient-specific questionsMature function; adult metabolic programmesWeeks–months
OrganoidArchitecture, cell–cell interaction, secretionVascular supply, immune cells, systemic hormonesWeeks–months
SpheroidGradients, penetration, 3D geometryStroma, vasculature, immune contextDays–weeks
MouseIntegrated physiology, chronic set pointHuman-specific biology; cost and throughputMonths
Human cohortThe disease itself, associationsCausation; mechanismYears

Important distinction. Each tier adds one thing and loses another. Moving up does not produce a better model of everything; it produces a model of more variables and fewer controls. A mouse is not a better cell than a hepatocyte; it is a different experiment.

What each tier is actually good for

ClaimMinimum tierReason
This enzyme controls this fluxLine or primaryMechanism is cell-autonomous
This compound reduces lipid accumulationLine, confirmed in primaryConvenience plus fidelity
This gene causes this metabolic phenotypeiPSC or mouseRequires genetic control in a physiological context
This pathway drives fibrosisCo-culture or organoidRequires matrix-depositing cells
This state promotes tumour growthMouseRequires a host
This metabolite predicts outcomeCohortRequires the disease population

Caveat on iPSC. iPSC-derived cells are fetal-like in metabolism: hepatocytes have low CYP and immature mitochondrial function, cardiomyocytes are glycolytic, neurons are immature. A disease phenotype that depends on adult metabolic programmes may not appear, and its absence is not evidence of absence.

The mouse, specifically

RequirementWhyCommonly missing
Diet composition in fullFat source and sucrose content change phenotype% kcal from fat only
Housing temperature22 °C is below thermoneutrality; chronic cold stressNot reported
Body compositionFat and lean mass divergeBody weight only
Pair-feedingSeparates composition from intakeAbsent in diet studies
Sex and littermatesSexually dimorphic; microbiota confoundSingle sex, non-littermates
Time of samplingGlucose tolerance varies across the light cycleSingle morning point
Genetic backgroundStrain differences in metabolic phenotypeMixed background

The second row is the one that most surprises: mice housed at standard temperature are cold, which raises energy expenditure and alters adipose and immune phenotypes — in the tissue most often being studied. A metabolic phenotyping paper that does not report housing temperature has an uncontrolled variable acting on the primary outcome.

The human cohort, specifically

DesignSupportsFails when
Cross-sectionalAssociationAny causal claim
ProspectiveTemporal orderReverse causation still possible
Mendelian randomisationCausal inference under assumptionsPleiotropy, weak instruments
InterventionShort-term causal effectLong-term outcome, adherence

Important distinction. A cohort measures the disease, not the mechanism. It supplies the effect size and the population, which is exactly what a model needs in order to be relevant — and exactly what most models are never calibrated against.

Decision sequence

  1. Write the claim as a single sentence with a tissue and a timescale.
  2. Identify the smallest tier that contains every element the sentence requires.
  3. Run the mechanism there.
  4. Confirm in one tier up, with the specific element that tier adds.
  5. Report which elements each tier supplied and which it did not.

Step 5 is what most papers omit, and it is what allows a reader to know how far the claim travels.

Failures that recur

  • • Convenience-first model choice, then a claim written to fit it.
  • • Immortalised line used for identity-dependent biology. HepG2 for hepatocyte function, 3T3-L1 for human adipose.
  • • iPSC-derived cells assumed mature. They are fetal-like.
  • • Mouse study without housing temperature or diet composition.
  • • Fibrosis claimed without matrix-depositing cells.
  • • Spheroid called a microenvironment. It is a gradient.
  • • Cohort association described as mechanism.
  • • No confirmation tier. A single-tier claim presented as general.

Where this connects

  • • Disease pillar supplies the tissue-and-timescale frame and the model requirements list this article operationalises.
  • • Glucose, lipid, amino acid and mitochondrial pillars supply the readouts appropriate to each tissue.
  • • MASH cell models, adipocyte models and spheroid articles supply the specific constraints of the three most commonly used systems.

Scientific interpretation and experimental design

  • • Answer the four questions first. Tissue, timescale, systemic component, architecture.
  • • Choose the smallest tier that contains every required element.
  • • Add one tier for confirmation, and name what it adds.
  • • Report the elements each tier lacked. That defines the claim's reach.
  • • Check iPSC maturity before interpreting a negative result.
  • • Report housing temperature and full diet composition.
  • • Calibrate models against cohort effect sizes where they exist.

Selected references for further reading

  • • Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.
  • • Febbraio MA, et al. Preclinical models for studying NASH-driven HCC: how useful are they? Cell Metabolism. 2019;29:18–26.
  • • Maloney SK, Fuller A, Mitchell D, Gordon C, Overton JM. Translating animal model research: does it matter that our rodents are cold? Physiology. 2014;29:413–420.
  • • Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery. Nature Reviews Genetics. 2019;20:377–388.
  • • Hirschhaeuser F, et al. Multicellular tumor spheroids: an underestimated tool is catching up again. Journal of Biotechnology. 2010;148:3–15.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: